JPRN-UMIN000010799招募中未知
Hematopoietic stem cell transplantation for patients with ischemic limbs - Therapeutic angiogenesis
Department of Internal Medicine and Clinical Immunology Yokohama City University Graduate School of Medicine0 个研究点目标入组 30 人开始时间: 2013年5月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •We exclude patients with severe involvement of the lung and heart. We also exclude patients with active retinopathy due to diabetes mellitus, with evidence of malignant disorder during the past 5 years, or with history of cerebral stroke during the past a year. Patients with a history of alcohol and/or drug dependency during the past 3 months are also excluded.
研究者
相似试验
尚未招募
1 期
Combined Infusion of Immune Cells and Vaccination to Boost Immunity to Infection After Bone Marrow TransplantatioACTRN12612000800820Professor DJ Gottlieb18
进行中（未招募）
不适用
onmyeloablative Hematopoietic Stem Cell Transplantation for Patients with High-Risk Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression with cyclophosfamide administered Before and After Transplantation. A monocentric study. - NDHigh risk Hematologic MalignanciesMedDRA version: 9.1Level: HLGTClassification code 10024324MedDRA version: 9.1Level: HLGTClassification code 10025323EUCTR2009-018083-94-ITISTITUTO EUROPEO DI ONCOLOGIA
招募中
1 期
Blood Stem Cell transplantation with low dose chemo/radiotherapy for patients with High-Risk solid tumors using related identical donors or 50% compatible donorsEUCTR2012-002464-27-ITISTITUTO EUROPEO DI ONCOLOGIA20
已完成
不适用
Allogeneic hematopoietic stem cell transplantation for elderly patientsJPRN-UMIN000017744nivesity of Tokyo Hospital, Department of Hematology and Oncology50
已完成
不适用
Allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-haploidentical related donor using reduced dose of posttransplantation high-dose cyclophosphamide (PTCy) for poor prognosis or refractory hematological malignancies (OCU16-2)Acute myeloid leukemia(AML) Acute lymphoblastic leukemia(ALL) Acute leukemias of ambiguous lineage Myelodysplastic syndrome(MDS) Chronic myeloid leukemia(CML) Adult T-cell leukemia/lymphoma(ATLL) Malignant lymphoma(ML)JPRN-UMIN000026028Osaka City University33